1. Home
  2. VRTX vs LMT Comparison

VRTX vs LMT Comparison

Compare VRTX & LMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • LMT
  • Stock Information
  • Founded
  • VRTX 1989
  • LMT 1912
  • Country
  • VRTX United States
  • LMT United States
  • Employees
  • VRTX N/A
  • LMT N/A
  • Industry
  • VRTX EDP Services
  • LMT Military/Government/Technical
  • Sector
  • VRTX Technology
  • LMT Industrials
  • Exchange
  • VRTX Nasdaq
  • LMT Nasdaq
  • Market Cap
  • VRTX 104.8B
  • LMT 105.1B
  • IPO Year
  • VRTX 1991
  • LMT N/A
  • Fundamental
  • Price
  • VRTX $484.74
  • LMT $448.10
  • Analyst Decision
  • VRTX Buy
  • LMT Buy
  • Analyst Count
  • VRTX 25
  • LMT 12
  • Target Price
  • VRTX $508.09
  • LMT $532.17
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • LMT 1.8M
  • Earning Date
  • VRTX 05-05-2025
  • LMT 04-22-2025
  • Dividend Yield
  • VRTX N/A
  • LMT 2.94%
  • EPS Growth
  • VRTX N/A
  • LMT N/A
  • EPS
  • VRTX N/A
  • LMT 22.31
  • Revenue
  • VRTX $11,020,100,000.00
  • LMT $71,043,000,000.00
  • Revenue This Year
  • VRTX $10.65
  • LMT $5.72
  • Revenue Next Year
  • VRTX $9.02
  • LMT $3.89
  • P/E Ratio
  • VRTX N/A
  • LMT $20.11
  • Revenue Growth
  • VRTX 11.66
  • LMT 5.14
  • 52 Week Low
  • VRTX $377.85
  • LMT $419.70
  • 52 Week High
  • VRTX $519.88
  • LMT $618.95
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 44.78
  • LMT 46.18
  • Support Level
  • VRTX $471.50
  • LMT $439.56
  • Resistance Level
  • VRTX $513.98
  • LMT $451.20
  • Average True Range (ATR)
  • VRTX 12.35
  • LMT 11.21
  • MACD
  • VRTX -4.12
  • LMT -1.48
  • Stochastic Oscillator
  • VRTX 27.48
  • LMT 41.61

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About LMT Lockheed Martin Corporation

Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.

Share on Social Networks: